Crimean-Congo hemorrhagic fever
disease diseaseOn this page
Also known as CCHFCongo feverCongo hemorrhagic feverCongo-Crimean hemorrhagic feverCrimean hemorrhagic feverCrimean hemorrhagic fever [CHF Congo virus]Crimean-Congo haemorrhagic fever
Summary
Crimean-Congo hemorrhagic fever (MONDO:0020501) is a disease and 7 clinical trials. Top therapeutic interventions include favipiravir and ribavirin. A subtype of viral hemorrhagic fever — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 78
- Clinical trials: 7
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | <1 / 1 000 000 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
78 HPO clinical features (Orphanet curated; top 50 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001873 | Thrombocytopenia | Very frequent (80-99%) |
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0003496 | Increased circulating IgM level | Very frequent (80-99%) |
| HP:0030005 | Capillary leak | Very frequent (80-99%) |
| HP:0000421 | Epistaxis | Frequent (30-79%) |
| HP:0002014 | Diarrhea | Frequent (30-79%) |
| HP:0002017 | Nausea and vomiting | Frequent (30-79%) |
| HP:0002027 | Abdominal pain | Frequent (30-79%) |
| HP:0002039 | Anorexia | Frequent (30-79%) |
| HP:0002240 | Hepatomegaly | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0003236 | Elevated circulating creatine kinase concentration | Frequent (30-79%) |
| HP:0003237 | Increased circulating IgG level | Frequent (30-79%) |
| HP:0003326 | Myalgia | Frequent (30-79%) |
| HP:0003645 | Prolonged partial thromboplastin time | Frequent (30-79%) |
| HP:0020071 | Viremia | Frequent (30-79%) |
| HP:0025258 | Stiff neck | Frequent (30-79%) |
| HP:0025435 | Increased circulating lactate dehydrogenase concentration | Frequent (30-79%) |
| HP:0030833 | Neck pain | Frequent (30-79%) |
| HP:0032198 | Decreased prothrombin time | Frequent (30-79%) |
| HP:0200026 | Ocular pain | Frequent (30-79%) |
| HP:0000225 | Gingival bleeding | Occasional (5-29%) |
| HP:0000509 | Conjunctivitis | Occasional (5-29%) |
| HP:0000613 | Photophobia | Occasional (5-29%) |
| HP:0000707 | Abnormality of the nervous system | Occasional (5-29%) |
| HP:0000712 | Emotional lability | Occasional (5-29%) |
| HP:0000713 | Agitation | Occasional (5-29%) |
| HP:0000790 | Hematuria | Occasional (5-29%) |
| HP:0000822 | Hypertension | Occasional (5-29%) |
| HP:0000952 | Jaundice | Occasional (5-29%) |
| HP:0000975 | Hyperhidrosis | Occasional (5-29%) |
| HP:0000979 | Purpura | Occasional (5-29%) |
| HP:0001259 | Coma | Occasional (5-29%) |
| HP:0001262 | Excessive daytime somnolence | Occasional (5-29%) |
| HP:0001289 | Confusion | Occasional (5-29%) |
| HP:0001399 | Hepatic failure | Occasional (5-29%) |
| HP:0001649 | Tachycardia | Occasional (5-29%) |
| HP:0001662 | Bradycardia | Occasional (5-29%) |
| HP:0001744 | Splenomegaly | Occasional (5-29%) |
| HP:0001882 | Leukopenia | Occasional (5-29%) |
| HP:0001974 | Leukocytosis | Occasional (5-29%) |
| HP:0002105 | Hemoptysis | Occasional (5-29%) |
| HP:0002248 | Hematemesis | Occasional (5-29%) |
| HP:0002249 | Melena | Occasional (5-29%) |
| HP:0002321 | Vertigo | Occasional (5-29%) |
| HP:0002380 | Fasciculations | Occasional (5-29%) |
| HP:0002615 | Hypotension | Occasional (5-29%) |
| HP:0002716 | Lymphadenopathy | Occasional (5-29%) |
| HP:0025143 | Chills | Occasional (5-29%) |
| HP:0031364 | Ecchymosis | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Crimean-Congo hemorrhagic fever |
| Mondo ID | MONDO:0020501 |
| MeSH | D006479 |
| Orphanet | 99827 |
| DOID | DOID:12287 |
| ICD-10-CM | A98.0 |
| ICD-11 | 1562906700 |
| NCIT | C34682 |
| SNOMED CT | 402919000 |
| UMLS | C0019099 |
| MedGen | 6800 |
| GARD | 0019690 |
| Is cancer (heuristic) | no |
Also known as: CCHF · Congo fever · Congo hemorrhagic fever · Congo-Crimean hemorrhagic fever · Crimean hemorrhagic fever · Crimean hemorrhagic fever [CHF Congo virus] · Crimean-Congo haemorrhagic fever
Disease family
This is a subtype of viral hemorrhagic fever. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › viral hemorrhagic fever › Crimean-Congo hemorrhagic fever
Related subtypes (15): Dengue hemorrhagic fever, arenavirus hemorrhagic fever, Ebola hemorrhagic fever, Venezuelan equine encephalitis, Lujo hemorrhagic fever, Bolivian hemorrhagic fever, Venezuelan hemorrhagic fever, Brazilian hemorrhagic fever, Chapare hemorrhagic fever, hantavirus pulmonary syndrome, Rift valley fever, Kyasanur forest disease, Omsk hemorrhagic fever, hemorrhagic fever-renal syndrome, Marburg hemorrhagic fever
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 3 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06860334 | PHASE2 | NOT_YET_RECRUITING | UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF |
| NCT00992693 | PHASE2 | WITHDRAWN | Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities |
| NCT05940545 | PHASE1/PHASE2 | UNKNOWN | UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF |
| NCT06799013 | PHASE1 | RECRUITING | Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever |
| NCT03020771 | PHASE1 | COMPLETED | Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans |
| NCT06684431 | PHASE1 | COMPLETED | Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever |
| NCT06624787 | Not specified | NOT_YET_RECRUITING | Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FAVIPIRAVIR | 4 | 2 |
| RIBAVIRIN | 4 | 1 |
Related Atlas pages
- Drugs: Favipiravir, Ribavirin